KB 8498
Alternative Names: KB-R8498Latest Information Update: 26 Mar 2008
Price :
$50 *
At a glance
- Originator Nippon Organon
- Class Antineoplastics; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Nov 1999 Kanebo's pharmaceutical business has been merged with Organon's Japanese operations to form Nippon Organon
- 05 Nov 1998 Profile reviewed
- 22 Mar 1997 Preclinical development for Solid tumours in Japan (PO)